NCT02172404已完成3 期
A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD.
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 160
- 主要终点
- Performance score based on the checklist for each device
研究概览
简要总结
Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
- •Historical data (not older than 6 months) of stable airway obstruction with an forced expiratory volume at one second (FEV1) ≤ 80% of predicted normal and FEV1 ≤ 70% of forced vital capacity (FVC)
- •Male or female patients with 40 years of age or older
- •Smokers or ex-smokers with a smoking history of more than 10 pack-years
- •Currently using a prescription bronchodilator (such as Atrovent®, Berodual®, Combivent®, salbutamol, etc.) administered at least once daily
- •Able to read and understand written instructions, understand verbal instructions and fill out written questionnaires regarding the devices
- •Able to give informed consent prior to participation in the trial, including discontinuation of any medications, sign an approved consent form, and be willing and able to complete all trial procedures
排除标准
- •Any acute or chronic illness which could interfere with the conduct of completion of the trial, including but not limited to cardiovascular, renal, neurologic, liver, immunologic, or endocrine dysfunction if clinically significant
- •Current or recent (past 2 years) history of drug or alcohol abuse
- •Participation in any other clinical trial or use if any investigational drug within the last 30 days prior to visit 1
- •Experience with the HandiHaler®
- •Discontinued use of regularly prescribed use of MDI within the last 12 months.
- •Treatment with any oral or injectable β-blockers within the recent 4 weeks prior to visit 1
- •Treatment with oral β-adrenergics within the recent 4 weeks prior to visit 1
- •Current or recent (last 6 weeks prior to visit 1) respiratory illness including, but not limited to upper or lower respiratory tract infections or asthma
- •Patients who are in a pulmonary rehabilitation program or who had completed a pulmonary rehabilitation program in the 6 weeks prior to visit 1
- •Patients with known hypersensitivity to ipratropium bromide, lactose or any other components of the inhalation capsule delivery system
- •Patients with known sensitivity to inhaled β-agonists
- •Patient using oral corticosteroid medication at unstable doses (i.e., less than 6 weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day
- •Pregnant or nursing women or women of childbearing potential not using medically approved means of contraception
研究组 & 干预措施
HandiHaler® vs. MDI
Experimental
sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
干预措施: Ipratropium metered dose inhaler (MDI) (Device)
MDI vs. HandiHaler®
Experimental
sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
干预措施: Ipratropium metered dose inhaler (MDI) (Device)
MDI vs. HandiHaler®
Experimental
sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
干预措施: Placebo capsule administered via the HandiHaler® (Device)
HandiHaler® vs. MDI
Experimental
sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
干预措施: Placebo capsule administered via the HandiHaler® (Device)
结局指标
主要结局
Performance score based on the checklist for each device
时间窗: Day 0 and 28
次要结局
- Number of incorrect answers to the "knowledge of use" questionnaire per device use(Day 28)
- Number of scoring attempts per device use(Day 0)
- Set of patient responses to the "ease of use" questionnaire(Day 28)
- Patients responses to the questionnaire(Day 28)
- Number of errors on all scoring attempts per device use(Day 0)
研究者
相似试验
已完成
3 期
The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal HypersensitivityDentine HypersensitivityNCT03072719GlaxoSmithKline120
已完成
3 期
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain TreatmentBack PainNCT01471886EMS83
招募中
不适用
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal MelasmaMelasmaNCT06278948Cosmetique Active International140
已完成
2 期
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT00742248Chiesi Farmaceutici S.p.A.54
已完成
3 期
A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug TreatmentEpilepsyNCT00210782Johnson & Johnson Pharmaceutical Research & Development, L.L.C.262